Communiqués Ocumension Therapeutics

Actions

1477

KYG674111011

Marché Fermé - Hong Kong S.E. Autres places de cotation 10:09:05 07/06/2024			Varia. 5j.	Varia. 1 janv.
6,77 ^HKD	-1,60 %		-0,15 %	+1,35 %

15/04	Ocumension Therapeutics annonce un essai clinique de phase III pour OT-502 en Chine	CI
08/04	Le médicament pour les yeux d'Ocumension Therapeutics achève ses essais cliniques et va bientôt déposer une demande d'enregistrement de nouveau médicament	MT

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

OcuMension (01477.HK) Invests Over RMB 123.8 Million in Research, Technology and Self-development Progress in Tandem, Main Product Sales Show Comprehensive Growth	21/03	PR
Nicox Provides First Half 2023 and Third Quarter 2023 Financial Results and Updates Key Milestones	23/10/23	AQ
Ocumension Therapeutics Announces 2023 Interim Results	24/08/23	AQ
Nicox's Partner Ocumension Therapeutics Receives Priority Review Status for ZERVIATE New Drug Application in China	28/04/23	AQ
Nicox, 2023 Ordinary Shareholder Meeting to be held on June 1st, 2023	25/04/23	AQ
Additional Future Royalty Revenue Stream for Nicox from 2024 following New Drug Application Submission for ZERVIATE in China	17/04/23	AQ
Ocumension Therapeutics Announces 2022 Annual Results	30/03/23	AQ
Nicox to Present at Upcoming Scientific Conferences	06/03/23	AQ
Nicox to Participate in Financial Pharmaceutical Industry and Scientific Events in H1 2023	25/01/23	AQ
EyePoint Pharmaceuticals and OcuMension Therapeutics Announce Approval of New Drug Application by China's NMPA for YUTIQ for the Treatment of Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye	22/06/22	AQ
Ocumension Therapeutics : INSIDE INFORMATION NEW DRUG APPLICATION OF OUR CORE PRODUCT OT-401 APPROVED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION	21/06/22	PU
EyePoint Pharmaceuticals and OcuMension Therapeutics Announce Approval of New Drug Application by China’s NMPA for YUTIQ® for the Treatment of Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye	21/06/22	AQ
Ocumension Therapeutics : Acquires all the Equity Interests in Two Ophthalmic Products Mainland China, Further Enhancing its Pipeline Strength	25/08/21	PR
Ocumension Therapeutics : Announces 2021 Interim Results	20/08/21	PR
Ocumension Therapeutics : NOTICE OF EXTRAORDINARY GENERAL MEETING	10/08/21	PU
OPKO Health : to Develop and Commercialize RAYALDEE in Greater China with Nicoya Therapeutics	22/06/21	AQ
Ocumension Therapeutics : VOLUNTARY ANNOUNCEMENT IND APPLICATION RECEIVED FOR A PHASE III CLINICAL TRIAL OF OT-101 IN CHINA	12/05/21	PU
Ocumension Therapeutics : COMPLETION OF THE TRANSACTIONS UNDER SHARE PURCHASE AGREEMENT	23/04/21	PU
Ocumension Therapeutics : VOLUNTARY ANNOUNCEMENT APPROVAL FOR COMMENCEMENT OF INITIAL PEDIATRIC STUDY PLAN FOR OT-101 IN THE UNITED STATES	22/04/21	PU
Ocumension Therapeutics : (I) DISCLOSEABLE TRANSACTIONS RELATING TO THE EXCLUSIVE LICENSE AGREEMENT AND THE SHARE PURCHASE AGREEMENT AND (II) THE WARRANT SUBSCRIPTION AGREEMENT WITH ALIMERA SCIENCES, INC.	14/04/21	PU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Ocumension Therapeutics

Actions

1477

KYG674111011

Communiqués

Filtres